Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer
- 1 June 2023
- journal article
- review article
- Published by Elsevier BV in European Urology
- Vol. 83 (6), 521-533
- https://doi.org/10.1016/j.eururo.2022.10.024
Abstract
No abstract availableKeywords
This publication has 100 references indexed in Scilit:
- Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the LiteratureEuropean Urology, 2015
- Surveillance or metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence (STOMP): study protocol for a randomized phase II trialBMC Cancer, 2014
- 18F NaF PET/CT in the Assessment of Metastatic Bone Disease: Comparison with Specific PET TracersPET Clinics, 2012
- 18F-fluorocholine for prostate cancer imaging: a systematic review of the literatureProstate Cancer and Prostatic Diseases, 2011
- Prospective Evaluation of 11C-Choline Positron Emission Tomography/Computed Tomography and Diffusion-Weighted Magnetic Resonance Imaging for the Nodal Staging of Prostate Cancer with a High Risk of Lymph Node MetastasesEuropean Urology, 2011
- Long-Term Risk of Clinical Progression After Biochemical Recurrence Following Radical Prostatectomy: The Impact of Time from Surgery to RecurrenceEuropean Urology, 2011
- MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort studyThe Lancet Oncology, 2008
- The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysisClinical Radiology, 2008
- Evidence of bias and variation in diagnostic accuracy studiesCMAJ : Canadian Medical Association Journal, 2006
- Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancerJournal of Cellular Biochemistry, 2003